News | November 02, 2012

Mevion Medical Systems Continues Manufacturing Ramp up for Mevion S250 Proton Therapy System

A fifth proton accelerator enters manufacturing line at Mevion headquarters

Mevion S250 Proton Therapy

November 2, 2012 —  Mevion Medical Systems announced the delivery of its fifth TriNiobium Core proton accelerator, the powerful proton source that is at the center of the revolutionary Mevion S250 Proton Therapy System. This accelerator will be delivered early next year to First Coast Oncology in Jacksonville, Fla. All 2013 and early 2014 Mevion S250 deliveries are already in the manufacturing stage.

“The Mevion S250 has redefined the economics, availability, and the future direction of proton therapy, by bringing the management and operation of proton therapy to the level of modern radiation therapy,” said Scot Ackerman, medical director for First Coast Oncology. “Our Mission has been to provide the most advanced radiation treatment for our cancer patients, and the Mevion S250 will allow us to offer to our patients the full benefits of proton therapy.”

The Mevion S250 proton therapy system represents the latest innovation in proton therapy, providing the same precise, non-invasive treatment advantages and capabilities of larger proton therapy systems but with a significantly reduced footprint, improved reliability, high patient throughput, more advanced clinical systems and lower implementation and operational costs. Powered by a patented gantry-mounted TriNiobium Core accelerator, the Mevion S250 has a footprint only slightly larger than a conventional linear accelerator.

In addition to the construction at First Coast Oncology, the Mevion S250 is installed at Washington University, St. Louis, Mo., and is under installation at Robert Wood Johnson University Hospital, New Brunswick, N.J. and Oklahoma University. An additional site in Florida, MD Anderson Cancer Center in Orlando just broke ground in September 2012.

More than a dozen Mevion S250 proton therapy systems are slated to be installed in the United States including five NCI Designated Comprehensive Cancer Center, and six international projects. “The simple and modular design of the Mevion S250 supports a lean and fast manufacturing process. This is a first in proton therapy which traditionally has been limited by the enormous size and complexity of the device”, says Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. The Mevion S250 is the only proton therapy system designed and manufactured in the United States, and has recently received United States Food and Drug Administration (FDA) 510(k) clearance and CE certification enabling Mevion customers to treat patients.

For more information: www.Mevion.com

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation
News | Proton Therapy | May 02, 2019
IBA (Ion Beam Applications SA) recently announced the first Flash irradiation in an IBA proton therapy gantry treatment...
Pencil Beam Scanning Better Protects Children With Brain Tumors
News | Proton Therapy | May 01, 2019
A comparison of three types of radiotherapy for children's brain tumors suggests a type of proton therapy called pencil...
California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment
News | Proton Therapy | April 25, 2019
California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Videos | Proton Therapy | March 01, 2019
ITN Associate Editor Jeff Zagoudis speaks with Mark Pankuch, Ph.D., director of physics and dosimetry at the...
Videos | Proton Therapy | February 28, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...